Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy
Patrizia Ferroni,
Fiorella Guadagni,
Silvia Riondino,
Ilaria Portarena,
Sabrina Mariotti,
Francesca La Farina,
Giovanni Davì,
Mario Roselli
Affiliations
Patrizia Ferroni
Biomarker Discovery and Advanced Biotechnology (BioDAT) Laboratory, IRCCS San Raffaele Pisana, Research Center, Italy
Fiorella Guadagni
Biomarker Discovery and Advanced Biotechnology (BioDAT) Laboratory, IRCCS San Raffaele Pisana, Research Center, Italy
Silvia Riondino
Biomarker Discovery and Advanced Biotechnology (BioDAT) Laboratory, IRCCS San Raffaele Pisana, Research Center, Italy;Department of Systems Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome “Tor Vergata”, Rome, Italy
Ilaria Portarena
Department of Systems Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome “Tor Vergata”, Rome, Italy
Sabrina Mariotti
Department of Systems Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome “Tor Vergata”, Rome, Italy
Francesca La Farina
San Raffaele Foundation, Ceglie Messapica Hospital, Ceglie Messapicaand, Italy
Giovanni Davì
Internal Medicine and Center of Excellence on Aging, “G. d’Annunzio” University Foundation, Chieti, Italy
Mario Roselli
Department of Systems Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome “Tor Vergata”, Rome, Italy
Mean platelet volume has been proposed as a predictor for venous thromboembolism in cancer. We, therefore, investigated the effects of different anti-cancer drugs on mean platelet volume in order to assess its possible value in the risk prediction of a first thromboembolic episode in cancer outpatients during treatment. Pre-treatment mean platelet volumes were retrospectively evaluated in 589 ambulatory patients at the beginning of a new chemotherapy regimen. Moreover, serial changes were evaluated at baseline and before each chemotherapy cycle on 385 of the 589 patients who consented to have additional blood withdrawals during treatment. Cox proportional hazards survival analysis demonstrated a 2.7 hazard ratio (P=0.01) of developing a first venous thromboembolic episode during chemotherapy for patients with baseline mean platelet volumes below the 10th percentile (
